You are now leaving the Kedrion Corporate site. The information available in your chosen website may not be in compliance with EU legislation regulating the advertising of medicinal products for human use, nor do the opinions expressed necessarily reflect the Company’s positions or are endorsed by it.
NO
YES

HIGHLIGHTS

EVENTS

Kedrion alongside IPOPI at the IPIC Congress in Madrid

The importance of early diagnosis and the most recent innovations in the treatment of PID patients were the focus

read more 

EVENTS

Kedrion keeps Hemophilia therapy debate flowing in Latin America

A recent CLAHT Congress symposium restates current and future role of replacement therapy

read more 

CORPORATE

FSI SGR enters Kedrion share capital

The company continues with its growth and development strategy

read more 

  1. EVENTS - 26-10-2018

    Kedrion renews its commitment to PID patients at ESID 2018

    18th edition of the Biennial Meeting of the European Society for Immunodeficiencies helds in Lisbon (Oct. 24 to 27)

    read more 

  2. EVENTS - 22-10-2018

    50 years of Anti-D celebrated at World Congress of Gynecology and Obstetrics in Rio De Janeiro

    Kedrion supports educational symposium to help Rh disease awareness and eradication

    read more 

  3. EVENTS - 18-10-2018

    EIGHT, the global educational initiative on Hemophilia A and its treatment

    Experts from all over the world attended the EIGHT 2018 Conference in Budapest, Hungary on 12-13 October

    read more 

  4. EVENTS - 02-10-2018

    Kedrion Biopharma participates in the Mother and Child Conference in Moscow

    A 50 years of Anti-D dedicated programme presented at the main Russian congress of Gynecology and Obstetrics

    read more 

Pages

For more information please contact: pressoffice@kedrion.com